已發(fā)表的部分文獻(xiàn): 標(biāo)題:Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.作者:Todorova K, Metodiev MV, Metodieva G, Mincheff M, Fern??ndez N, Hayrabedyan S;雜志名稱:Horm Cancer 標(biāo)題:TGF-?21 increases viral burden and promotes HIV-1 latency in primary differentiated human bronchial epithelial cells.作者:Chinnapaiyan S, Dutta RK, Nair M, Chand HS, Rahman I, Unwalla HJ;雜志名稱:Sci Rep 標(biāo)題:LncRNA SNHG16 induced by TFAP2A modulates glycolysis and proliferation of endometrial carcinoma through miR-490-3p/HK2 axis.作者:Zhang G, Ma A, Jin Y, Pan G, Wang C;雜志名稱:Am J Transl Res 標(biāo)題:METTL3-mediated pre-miR-665/DLX3 m6A methylation facilitates the committed differentiation of stem cells from apical papilla.作者:Gu T, Guo R, Fang Y, Xiao Y, Chen L, Li N, Ge XK, Shi Y, Wu J, Yan M, Yu J, Li Z;雜志名稱:Exp Mol Med 標(biāo)題:dCas9-HDAC8-EGFP fusion enables epigenetic editing of breast cancer cells by H3K9 deacetylation.作者:Rahman MM, Tollefsbol TO;雜志名稱:Eur J Cell Biol Epigentek 公司是全球領(lǐng)先的表觀遺傳學(xué)相關(guān)研究的技術(shù)創(chuàng)新者和產(chǎn)品開發(fā)供應(yīng)商。開發(fā)了超過700多個專利產(chǎn)品,為表觀遺傳學(xué)方面的研究和新藥研發(fā)提供全面系統(tǒng)的解決方案,涵蓋樣品制備、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、組蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等領(lǐng)域,提供小分子抑制劑、蛋白質(zhì)、抗體、以及分析試劑盒產(chǎn)品。